PetrosGeorgeNikolinakosMD

Hematologic Oncology

Adjunct Associate Professor UGA, Director of Clinical Research, Managing Partner Hematology and Medical Oncology, University Cancer & Blood Center, LLC

Join to view full profile

Dr. Nikolinakos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Nikolinakos' full profile

Already have an account?

Office
3320 Old Jefferson Rd
Ste 700
Athens, GA 30607
Phone+1 706-353-2990

Fax+1 706-353-2992
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Cook County Health and Hospitals SystemChief Residency, Internal Medicine, 2001 - 2002
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1998 - 2001
University of Debrecen Medical and Health Science CenterClass of 1996

Certifications & Licensure

GA State Medical License 2009 - 2024
TX State Medical License 2007 - 2023
IL State Medical License 1998 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Clinical Trials Participation Award Conquer Cancer Foundation of ASCO, 2013

Clinical Trials

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) Start of enrollment: 2012 Dec 11
Terminated
Phase 3
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Start of enrollment: 2014 Mar 01
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Start of enrollment: 2015 Aug 01
Completed
Phase 2
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors Start of enrollment: 2015 Aug 31
Completed
Phase 1
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Active, not recruiting
Phase 2
A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Start of enrollment: 2016 May 24
Completed
Phase 3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2016 Jun 01
Active, not recruiting
Phase 3
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Start of enrollment: 2017 Feb 22
Completed
Phase 2
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 3
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Start of enrollment: 2017 May 01
Completed
Phase 2
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Start of enrollment: 2017 Jul 07
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

CTC-Race: Single-Cell Motility Assay of Circulating Tumor Cells from Metastatic Lung Cancer Patients.
Yang Liu, Wujun Zhao, Jamie Hodgson, Mary Egan, Christen N Cooper Pope, Glenda Hicks, Petros G Nikolinakos, Leidong Mao> ;ACS Nano. 2024 Mar 26
1 citations
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from...
Guy Jerusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Petros Nikolinakos, Felipe Ades, Jeiry Filian, Ning Huang, Antonella Mazzei-Abba, Sara M T...> ;Breast. 2023 Dec 1
5 citations
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Alexander Spira, Michael S Wertheim, Edward J Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James ...> ;The Oncologist. 2023 Feb 8
22 citations
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Monta...> ;Clinical Cancer Research. 2022 Aug 2
3 citations
Simultaneous biochemical and functional phenotyping of single circulating tumor cells using ultrahigh throughput and recovery microfluidic devices.
Yang Liu, Wujun Zhao, Rui Cheng, Jamie Hodgson, Mary Egan, Christen N Cooper Pope, Petros Nikolinakos, Leidong Mao> ;Lab on a Chip. 2021 Sep 14
9 citations
Label-free inertial-ferrohydrodynamic cell separation with high throughput and resolution.
Yang Liu, Wujun Zhao, Rui Cheng, Alicia Puig, Jamie Hodgson, Mary Egan, Christen N Cooper Pope, Petros Nikolinakos, Leidong Mao> ;Lab on a Chip. 2021 Jul 13
7 citations
Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort.
Rachel Martini, Yalei Chen, Brittany D. Jenkins, Isra A. Elhussin, Esther Cheng, Syed A. Hoda, Paula S. Ginter, Jeffrey Hanover, Rozina B. Zeidan, Joseph K. Oppong, Er...> ;Scientific Reports. 2021 Apr 29
3 citations
Fundamentals of integrated ferrohydrodynamic cell separation in circulating tumor cell isolation
Yang Liu, Wujun Zhao, Rui Cheng, Bryana N. Harris, Jonathan R. Murrow, Jamie Hodgson, Mary Egan, Anastacia Bankey, Petros Nikolinakos, Travis Laver, Kristina Meichner,...> ;Lab on a Chip. 2021 May 4
34 citations
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, Jonathan M. Lehman, Daniel Morgensztern, Jyoti D. Patel, John Wrangle, Giuseppe Curigliano, Laurent Greillier, Meliss...> ;Journal of Thoracic Oncology. 2021 Feb 27
27 citations
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral ...
Patrick B. Johnston, Amanda F. Cashen, Petros Nikolinakos, Anne W. Beaven, Stefan K. Barta, Gajanan Bhat, Steven J. Hasal, Sven de Vos, Yasuhiro Oki, Changchun Deng, F...> ;Experimental Hematology & Oncology. 2021 Feb 18
31 citations
Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype
Monique B. Nilsson, Jacqulyne P. Robichaux, Matthew H. Herynk, Tina Cascone, Xiuning Le, Yasir Elamin, S. Patel, Fahao Zhang, Li Xu, L. Hu, Lixia Diao, Li Shen, Junqin...> ;Journal of Thoracic Oncology. 2021 Mar 1
62 citations
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
James Chih-Hsin Yang, D. Ross Camidge, Cheng-Ta Yang, Jianying Zhou, Renhua Guo, Chao Hua Chiu, Gee-Chen Chang, Her Shyong Shiah, Yuan Chen, Chin Chou Wang, David Berz...> ;Journal of Thoracic Oncology. 2020 Dec 1
91 citations
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen A. Hussein, Robert M. Jotte, Leora Horn, Davey B. Daniel, George P. Keogh, Ben C. Creela...> ;Journal of Clinical Oncology. 2020 Sep 10
93 citations
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Jared Weiss, Tibor Csoszi, M. Maglakelidze, Robert Hoyer, J.T. Beck, M. Domine Gomez, A. Lowczak, Raid Aljumaily, C.M. Rocha Lima, Ralph V. Boccia, Wahid Hanna, Petros...> ;Annals of Oncology. 2019 Oct 1
93 citations
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Alexa B. Schrock, Viola W. Zhu, Wen-Son Hsieh, Russell Madison, Benjamin Creelan, Jeffrey Silberberg, Dan Costin, Anjali Bharne, Ioana Bonta, Thangavijayan Bosemani, P...> ;Journal of Thoracic Oncology. 2018 Sep 1
24 citations
Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells
Wujun Zhao, Yang Liu, Brittany D. Jenkins, Rui Cheng, Bryana N. Harris, Weizhong Zhang, Jin Xie, Jonathan R. Murrow, Jamie Hodgson, Mary Egan, Ana Bankey, Petros Nikol...> ;Lab on a Chip. 2019 May 14
35 citations
Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry
Brittany D. Jenkins, Rachel Martini, Rupali Hire, Andrea Brown, Briana Bennett, I'nasia Brown, Elizabeth W. Howerth, Mary Egan, Jamie Hodgson, Clayton Yates, Rick A. K...> ;Cancer Epidemiology, Biomarkers & Prevention. 2019 Apr 1
83 citations
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
, , , , , , , , , , , , , , , , , , , , , > ;Cancer Discovery. 2019 Mar 1
492 citations
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Dirix, István Takács, Guy Jerusalem, Petros Nikolinakos, Hendrik Tobias Arkenau, Andres Forero-Torres, Ralph V. Boccia, Marc E. Lippman, Robert Somer, Martin Smaka...> ;Breast Cancer Research and Treatment. 2018 Oct 23
68 citations
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
Filippo Pietrantonio, F. Di Nicolantonio, Alexa B. Schrock, J.W. Lee, Federica Morano, Giovanni Fucà, Petros Nikolinakos, A. Drilon, J.F. Hechtman, Jason H. Christians...> ;Annals of Oncology. 2018 Jun 1
13 citations
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
David M. Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason C. Chandler, Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth B. Blankstein, Petro...> ;Cancer Chemotherapy and Pharmacology. 2018 Feb 13
55 citations
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously expos...
Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Khalil, Daruka Mahadevan, Changchun Deng, Jennifer E Amengual, Petros Nikolinakos, Jill M. Kolesar, John G...> ;British Journal of Haematology. 2017 Apr 1
1 citations
P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153: Track: Immunotherapy
David M. Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason C. Chandler, Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth B. Blankstein, Petro...> ;Journal of Thoracic Oncology. 2016 Oct 1
492 citations
Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau, Eric A. Collisson, Stephen G. Divers, Dave S.B. Hoon, E. Scott Kopetz...> ;Plos One. 2015 Oct 16
72 citations
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI
Samuel J. Klempner, Lyudmila Bazhenova, Fadi Braiteh, Petros Nikolinakos, Kyle Gowen, Claudia M. Cervantes, Juliann Chmielecki, Joel R. Greenbowe, Jeffrey S. Ross, Phi...> ;Lung Cancer. 2015 Sep 1
Join now to see all

Journal Articles

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously expos...
Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Y. Khalil, Daruka Mahadevan, Changchun Deng, Jennifer E. Amengual, Petros G. Nikolinakos, Jill M. Kolesar,..., Br J Haematol, 1/1/2017
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Permetrexed versus Paclitaxel + Carboplatin + Bevaciz...
Ralph G. Zinner, MD, Coleman K. Obasaju, MD, PhD, David R. Spigel, MD, Robert W. Weaver, MD, J. Thaddeus Beck, MD, David M. Waterhouse, MD, MPH, Manuel R. Modiano, MD,..., J Thorac Oncol, 1/1/2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy ...
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki ..., Lancel Oncol, 1/1/2015
Two Genomic Strategies in Non-Small Cell Lung Cancer Prognosis
Nikolinakos P, Lippman SM, Abstracts in Hematology and Oncology, 1/1/2007
Photo Quiz Back Rash
Shekarappy RJ, Nikolinakos P, Bansidhar T, Sistoza E, Smith J, Am Fam Physician, 1/1/1999
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell Free Circulating Tumor DNA
Richard B. Lanman, Stefanie A. Mortimer, Oliver A. Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau, Eric A. Collisson, Stephen G. Divers, Dave S.B. Hoon, E. Scott Kop..., PLOS ONE, 1/16/2015
High Pathologic Complete Response in HER2-Positive, Early-Stage Breast Cancer to a Novel Non-Anthracycline Neoadjuvant Chemotherapy
Amelia Zelnak, Petros Nikolinakos, Jayanthis Srinivasiah, William Jones, Andrew Pippas, Yuan Liu, Xiaoxian Li, Mylin Torres, Ruth M. O'Regan, Clinical Breast Cancer
Epiderman Growth Factor Receptor Regulated MET Levels and Invasiveness Through Hypoxia-Inducible Factor-1alpha in Non-Small Cell Lung Cancer Cells
Xu L, Nilsson MB, Saintignv P, Cascone T, Herynk MH, DU Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie ..., Oncogene, 1/15/2010
Join now to see all

Abstracts/Posters

Emergence of RET Rearrangement Co-Existing with Activated EGFR Mutation in EGFR-Mutated NSCLC Patients Who Had Progressed on First- or Second-Generation EGFR TKI
Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH, 1/1/2015
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive (HER2+) Breast Cancer
Lee S. Schwartzberg, MD; Kurt W. Tauer, MD; Robert C. Hermann, MD; Petros G. Nikolinakos, MD; Arthur C. Houts, PhD, J Clin Oncol, 1/1/2013
Reverse-Phase Protein Array (RPPA) Profiling of Response to Taxanes and Epidermal Growth Factor Receptor (EGFR) Inhibitors Identifies an Inverse Correlation Between Ma...
Lauren Averett Byers, Meera Nanjundan, Luc Girard, Kevin Coombes, Yang Xie, Michael Peyton, Sunny Zachariah, Stephanie Weber, Doris Siwak, Petros Nikolinakos, Gordon M..., AACR Meeting, 1/1/2008
Differential Regulation Hypoxia Inducible Factor (HIF)-1alpha and -2alpha in Human NSCLC Cell Lines Bearing Wild Type and Mutated EGFR
Tina Cascone, Petros Nikolinakos, Li Xu, Matthew Herynk, Monique Nilsson, and John Heymach, AACR Meeting, 1/1/2008
Analyses of Plasma Cytokine/Angiogenic Factors (C/AFs) Profile During Preoperative Treatment with Pazopanib (GW786034) in Early-Stage Non-Small Cell Lung Cancer
Petros Nikolinakos, N. Altorki, M. Guarino, H. Tran, D. Rajagopalan, S. Swann, W. Bordogna, L. Ottesen, D. Yankelevitz, J.V. Heymach, J Clin Oncol, ASCO, 1/1/2008
Reverse-Phase Protein Array (RPPA) Profile of Non-Small Cell Lung Cancer Lines Identifies Tumor Signatures for Sensitivity and Resistance to Chemotherapy and Targeted ...
Byers, Lauren Averett, Nanjundan, Meera, Girard, Luc, Coombes, Kevin, Xie, Yang, Peyton, Michael, Ma, Yao, Zachariah, Sunny, Nikolinakos, Petros, Minna, John, Heymach,..., AACR Meeting, 1/1/2007
Trilaciclib (GIT28), a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Etoposide and Carboplatin (EP) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): ...
Caio Max S, Rocha Lima, Patrick J. Roberts, Victor M. Priego, Stephen G. Divers, Melanie B. Thomas, Ralph V. Boccia, Katie Stabler, Elizabeth Andrews, Rajesh K. Malik,...
Safety Profile of Nivolumad Administered as 30-Minute (min) Infusion: Analysis of Data From CheckMate 153
David Michael Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason Claud Chandler, Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth Bruce Blanks...
Colorectal Cancer (CRC) Cohort Analysis of Patients Treated with Buparlisib in a Distinctive Tissue-Agnostic Trial Model for Molecularly Pre-Selected Tumors
Sarina Anne Piha-Paul, James A. Knost, Petros Nikolinakos, Lee Steven Schwartzberg, Denise A. Yardley, Eric Daniel Slosberg, Barinder Kang, Theresa White, Claudia Lebe...
Impact of Next-Generation Sequencing (NGS) on Treatment Decision in the Community Oncology Setting
Lindsay Carol Overton, Christopher L. Corless, Manish Agrawal, Vasily J. Assikis, Nancy L. Beegle, Sibel Blau, Marc Chernoff, Stephen G. Divers, David H. Henry, Petros...
Results of a Phase I Dose-Escalation Trial with Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Patients with Rituximab Relapsed/Refractory Lymp...
Owen A. O'Connor, MD, PhD, Changchun Deng, MD, PhD, Jennifer E. Amengual, MD, Marshall Schreeder, MD, Daruka Mahadevan, MD, Mazen Y. Khalil, MD, Petros Nikolinakos, MD...
Join now to see all

Press Mentions

University Cancer & Blood Center Covington Facility Moves to New LocationDecember 15th, 2022
University Cancer & Blood Center Hosts A Community Conversation: Living with Lung CancerJanuary 18th, 2016